on ADOCIA (EPA:ADOC)
Adocia: Financial report for the fourth quarter of 2024
Biopharmaceutical company Adocia, which specializes in treating diabetes and obesity, has released its financial results for the last quarter of 2024. The company's cash position stands at €7.5 million as of December 31, 2024, compared to €13 million at the end of 2023. This decline reflects the year's operational activities and strategic investments.
Adocia reported revenue of €9.3 million for the quarter, driven by a $10 million milestone payment from Tonghua Dongbao related to the BioChaperone® Lispro study. The company is continuing its partnership discussions with Sanofi for M1Pram, and is also focusing on the development of BioChaperone® CagriSema.
The company also highlighted its AdoShell® technology for cell therapy, highlighting significant preclinical advances. Adocia plans to continue its collaboration for the AdOral® technology, focused on the oral delivery of peptides.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ADOCIA news